ANI Pharmaceuticals Inc. (ANIP)’s Financial Results Comparing With Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS)

ANI Pharmaceuticals Inc. (NASDAQ:ANIP) and Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS), are influenced by compare since they are both players in the Biotechnology. These factors are particularly influence the risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation of the two firms.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ANI Pharmaceuticals Inc. 69 4.66 9.22M 1.15 73.62
Sunesis Pharmaceuticals Inc. 1 -0.02 82.01M -0.64 0.00

Table 1 showcases the top-line revenue, earnings per share and valuation of ANI Pharmaceuticals Inc. and Sunesis Pharmaceuticals Inc.


Table 2 has ANI Pharmaceuticals Inc. and Sunesis Pharmaceuticals Inc.’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
ANI Pharmaceuticals Inc. 13,300,634.74% 7% 3.1%
Sunesis Pharmaceuticals Inc. 9,570,544,987.75% 209% -116.3%

Risk and Volatility

A beta of 2.16 shows that ANI Pharmaceuticals Inc. is 116.00% more volatile than Standard and Poor’s 500. Competitively, Sunesis Pharmaceuticals Inc.’s beta is 2.79 which is 179.00% more volatile than Standard and Poor’s 500.


The Current Ratio and a Quick Ratio of ANI Pharmaceuticals Inc. are 0.9 and 0.7. Competitively, Sunesis Pharmaceuticals Inc. has 2.6 and 2.6 for Current and Quick Ratio. Sunesis Pharmaceuticals Inc.’s better ability to pay short and long-term obligations than ANI Pharmaceuticals Inc.

Analyst Ratings

ANI Pharmaceuticals Inc. and Sunesis Pharmaceuticals Inc. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
ANI Pharmaceuticals Inc. 0 0 1 3.00
Sunesis Pharmaceuticals Inc. 0 0 0 0.00

ANI Pharmaceuticals Inc.’s upside potential is 1.89% at a $74.5 average target price.

Institutional and Insider Ownership

ANI Pharmaceuticals Inc. and Sunesis Pharmaceuticals Inc. has shares owned by institutional investors as follows: 86.2% and 41.4%. Insiders owned 3.3% of ANI Pharmaceuticals Inc. shares. Comparatively, Sunesis Pharmaceuticals Inc. has 0.2% of it’s share owned by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
ANI Pharmaceuticals Inc. 1.72% 2.27% 20.43% 55.98% 25.49% 87.89%
Sunesis Pharmaceuticals Inc. 21.13% 30.3% -36.3% 66.19% -61.78% 106.88%

For the past year ANI Pharmaceuticals Inc. was less bullish than Sunesis Pharmaceuticals Inc.

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and Hydrocortisone Enema and Cortenema to treat ulcerative colitis. It also provides Hydrocortisone Rectal Cream to treat inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; Lithium Carbonate ER and Lithobid for bipolar disorder; Mesalamine Enema to treat distal ulcerative colitis, proctosigmoiditis, or proctitis; Methazolamide to treat ocular conditions; and Metoclopramide and Reglan to treat gastroesophageal reflux. In addition, the company offers Nilutamide to treat metastatic prostate cancer; Nimodipine that reduces the ischemic deficits in patients with subarachnoid hemorrhage; Opium Tincture to treat diarrhea; Oxycodone capsules and oral solution for pain; Propafenone to treat arrhythmia; Propranolol ER and Inderal LA for managing hypertension in patients with angina pectoris; and Vancomycin and Vancocin for use in treating C. difficile-associated diarrhea and enterocolitis. Further, it provides contract manufacturing services for other pharmaceutical companies. The company markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. ANI Pharmaceuticals, Inc. is headquartered in Baudette, Minnesota.

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company is developing vosaroxin, an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). It has completed a Phase III, randomized, double-blind, and placebo-controlled trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML. The company also completed a Phase II single-agent trial of vosaroxin in platinum-resistant ovarian cancer. In addition, it is involved in the initiation of an investigator-sponsored trial of vosaroxin in combination with decitabine in older patients with untreated AML and high-risk myelodysplastic syndrome; and developing SNS-062, a non-covalently binding inhibitor of the human protein BrutonÂ’s tyrosine kinase (BTK). The company has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of phosphoinositide-dependent kinase-1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.